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CirCulating MelanoMa Cells
Molecular markers have been increasingly 
applied in cancer to assess metastatic risk 
and to guide treatment, including in mela-
noma, where assessment of BRAF mutations 
in tumor tissues to determine suitability for 
treatment with vemurafenib is now rou-
tine (1). Static assessment of tumor tissues, 
however, does not indicate whether tumor 
cells are being shed or whether treatment 
is reducing metastasis. Because melanoma 
metastasizes hematogenously, examination 
of circulating melanoma cells (CMC) is a 
logical as well as a convenient alternative to 
the  examination of tumor tissues. A reliable 
assessment of CMC numbers and molecular 
signatures could have major clinical impact. 
The failure to demonstrate a survival advan-
tage for  adjuvant treatment might be linked 
to inadequate disease staging and, conse-
quently, inadequate assessment of relapse 
risk. Because CMC may indicate systemic 
subclinical disease, their detection and analy-
sis may be useful not only for staging/progno-
sis but also for assessing response to adjuvant 
therapy. The discovery of CMC theoretically 
would also allow for earlier detection of 
metastasis. This could potentially increase the 
effectiveness of existing therapies. Serial CMC 
assessments during  treatment may allow for 
the earlier assessment of response, sparing 
non-responding patients toxicities. Serial 
CMC assessments could help determine 
the mechanisms of resistance and suggest 
 interventions to address them. Furthermore, 
not all patients with melanoma are candidates 
for surgery to obtain tissue for analysis of 
molecular markers, and CMC would provide 
a liquid biopsy of sum total of tumors at all 
the sites in the patient.
PolyMerase Chain reaCtion 
aPProaChes
Polymerase chain reaction (PCR)-based 
techniques that detect the expression of the 
mRNA/transcripts of  melanocyte-associated 
factors, such as tyrosinase and Melan-A, in 
nucleated blood cells and present in cell 
free fraction have been best studied clini-
cally. They have demonstrated promise in 
melanoma surveillance and in monitoring 
adjuvant and metastatic therapy (2–4). 
They can also be combined with assess-
ment of circulating DNA for melanoma-
associated mutations, which in itself can 
be used to infer the presence of CMC (5). 
No PCR-based approach, however, has been 
validated for clinical use, due to limitations 
in consistency and high false negative rates. 
These approaches cannot quantify the num-
ber of CMC, and morphologic evaluation of 
the cells cannot be obtained. The presence 
of normal cellular transcripts by leukocytes, 
which contribute most of the total nucleo-
tides extracted, may dilute those that are 
tumor-related, even following substantial 
enrichment for CMC (6). Furthermore, 
tumor heterogeneity may lead to clones 
of cells that do not express the melanocyte 
marker. There are technical issues. RNA is 
inherently labile (7). Differences in the PCR 
methodologies applied as well as differences 
in data interpretation may also be respon-
sible for the disparate findings of various 
studies. Because cells are not captured, the 
ability to evaluate changes in targets or bio-
logical characteristics is limited, particularly 
in the context of the tumor heterogeneity 
that characterizes melanoma (8).
CytoMetriC aPProaChes
Techniques that isolate and enumerate 
morphologically identified CMC have also 
been studied. Although several steps can 
be involved, molecular characterization of 
the CMC isolated has been accomplished. 
Typically, cytometric approaches have two 
components: a preparative and an analyti-
cal one. Preparative enrichment is required 
because CMC are rare in the blood, at counts 
lower than 10/ml of whole blood (as low 
as 1 CMC per 1,000,000 leukocytes). The 
goal is to increase sensitivity. The  analytical 
step eliminates the non-relevant blood 
cells in the enriched fraction. The goal is to 
increase specificity. Here the greatest con-
cern is again false negative results. Despite 
an abundance of potential markers, a con-
sensus on how melanoma cells circulate, 
their phenotype, and the optimal capture 
reagent have not been established. Tumor 
cells in circulation may not always exhibit 
the criteria used to identify them in the 
context of tissue biopsy. The CellSearch® 
system (Veridex LLC, Raritan, NJ, USA), a 
cytometric approach based on the immu-
nomagnetic capture of circulating EpCAM-
positive tumor cells, has been approved by 
the U.S. Food and Drug Administration 
to monitor the effectiveness of therapy in 
patients with metastatic breast, colorectal, 
and prostate carcinomas (9). No cytometric 
method has been validated for clinical use 
in melanoma. Representative approaches 
applied include the following:
PhysiCal
Density gradient separations with for exam-
ple, Ficoll, combined with elimination of 
erythrocytes using isotonic ammonium 
chloride lysis method have been applied 
(10). The advantages of these approaches are 
simplicity and lower costs. However, these 
techniques typically have unacceptably high 
cell losses and thus lack sensitivity. Several 
platforms, including filter-based micro-
devices, or microfluidic devices, using size 
as the capture method have been described 
(11, 12). Given their heterogeneity, it is not 
clear that large size is a sufficient criterion 
to capture all CMC. Dielectrophoretic 
forces have been applied, and cells of dif-
ferent types have been separated, without 
interfering with their viability, according 
to their dielectric and hydrodynamic flow 
properties (13). These approaches may be 
applicable to CMC but have not yet been 
effectively applied clinically.
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rarity of CMC make this technique by itself 
less practical (19). High speed scanning 
microscopy techniques such as fiber-optic 
based automated scanning technology 
and laser microdissection may be used in 
identifying and enumerating CMC that 
are identified with fluorescently tagged 
melanocyte-associated markers (20, 21). 
Combining these technologies with unique 
chip-based substrates has made possible 
the molecular characterization of single 
melanoma cells (21).
suMMary
Polymerase chain reaction-based approaches 
to enumerate rare and heterogeneous CMC 
have demonstrated promise but do not 
allow for morphologic or molecular analysis 
of specific cell populations. Although cyto-
metric approaches are in clinical use in the 
management of patients with carcinomas, 
the development of similarly approved 
technology for CMC has proven challenging 
because of the lack of specific, cell-surface, 
CMC capture antigen(s). Analysis of the 
captured cells, such as the identification of 
molecular targets or special biological char-
acteristics, with current methods can also be 
cumbersome. Thus, there remains a need 
for the development of a reliable, efficient 
platform to isolate, enrich, and character-
ize CMC in blood. Molecular assessments 
are now impacting melanoma management. 
Given the multitude of therapeutic tar-
gets emerging, whole genome sequencing 
adapted to enriched CMC obtained from 
peripheral blood samples will be necessary 
for meaningful evaluation of therapeutic 
directions, and given tumor heterogeneity, 
it will most likely need to be aimed at the 
single cell level.
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iMMunoMagnetiC – Positive seleCtion
Circulating melanoma cells have been posi-
tively selected using immunomagnetic cell 
enrichment technique with antibody to, 
for example, the high molecular weight- 
melanoma-associated antigen (HMW-
MAA). Cells isolated have been assessed 
for BRAF status (14). CellSearch® technol-
ogy has also been applied to CMC (15). 
Magnetic particles are tagged with anti-
bodies against the melanoma-associated 
cell-surface antigen CD146 and captured 
in a magnet. These cells are detected using 
microscopy by fluorescently tagged anti-
body to HMWMAA (15). The caveat of 
this technology is the non-specificity of the 
capture antigen. CD146 is also expressed on 
circulating endothelial cells. It is also not 
known whether all CMC express CD146. 
Hence, sensitivity of this approach is 
unclear. Multiple antibody-bound beads 
were suggested to increase the sensitivity 
of positive selection of CMCs, however, the 
approach may add to the complexity of the 
microscopic image analysis and interpreta-
tion (16).
iMMunoMagnetiC – negative seleCtion
Negative immunomagnetic selection is an 
attractive approach for isolating CMC in the 
absence of reliable CMC surface markers. 
Antibodies tagged with magnetic particles 
against CD45 antigen present ubiquitously 
on leukocytes are used to magnetically 
deplete a blood sample of white cells. 
These remaining non-magnetic cells are 
analyzed for CMC with melanocyte-asso-
ciated markers, such as Melan-A/MART-
1, HMB-45, and S100B. The advantage of 
this technique is unbiased capture of non-
leukocytic cells, and disadvantage is lower 
purity of the CMC due to less than 100% 
capture of leukocytes. Negative separation 
has been successfully used to isolate CMC, 
and also offers the possibility of molecular 
characterization (17, 18). Although CMC 
prepared by this method are not pure, due 
to less than complete depletion of leuko-
cytes, this disadvantage may be outweighed 
by the presumed complete capture of all 
types of CMC.
autoMated CytoMetriC Methods
Flow cytometry methods using antibod-
ies against melanocyte determinant have 
been used to identify and capture CMC. 
However, the throughput is low, and the 
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